 Syndax Pharmaceuticals Inc NASDAQ: SNDX, in its Q1 earnings, also announced new data from the ongoing Phase 1 dose-escalation portion of the Phase 12 AUGMENT-101 trial evaluating SNDX-5613 in patients with MLLr and NPM1c mutant relapsedrefractory RR acute leukemias. The new data showed that two prior responders have improved from a complete response with incomplete platelet recovery CRp to a complete response CR with no evidence of minimal residual disease MRD 